Показати простий запис статті
dc.contributor.author |
Smorodin, E.P. |
|
dc.contributor.author |
Sergeyev, B.L. |
|
dc.date.accessioned |
2018-06-17T20:26:46Z |
|
dc.date.available |
2018-06-17T20:26:46Z |
|
dc.date.issued |
2016 |
|
dc.identifier.citation |
The level of IgG antibodies reactive to TF, Tn and Alpha-Gal polyacrylamide-glycoconjugates in breast cancer patients: relation to survival / E.P. Smorodin, B.L. Sergeyev // Experimental Oncology. — 2016 — Т. 38, № 2. — С. 117-121. — Бібліогр.: 31 назв. — англ. |
uk_UA |
dc.identifier.issn |
1812-9269 |
|
dc.identifier.uri |
http://dspace.nbuv.gov.ua/handle/123456789/137989 |
|
dc.description.abstract |
Background: The serum levels of IgG antibodies reactive to glycoconjugates (TF, Tn and αGal) were found to be associated with prognosis of gastrointestinal cancer patients. Aim: To study the relation between the levels of serum antibodies to TF-pAA, Tn-PAA and αGal-PAA polyacrylamide-based glycoconjugates and survival in breast cancer. Materials and Methods: The preoperative level of IgG antibodies was analysed in the serum of patients (n = 59) using ELISA with polyacrylamide-glycoconjugates namely, TF-pAA (amide-type), and ethanolamide-conjugates Tn-PAA and αGal-PAA. Survival rate and hazard ratio (HR) were assessed by the Kaplan — Meier method and Cox univariate analysis in different pathomorphological groups. Results: Significantly better survival was observed in patients with an increased level of anti-TF-pAA antibodies both for all patients in total and groups in stages II–III; N1–2 and G3 (p = 0.008–0.021, HR = 0.18–0.23, mean survival time in months 164–186 vs 69–121). A trend to worse survival was observed in increased level of anti-Tn IgG (stages II–III) and anti-αGal IgG (G3): p = 0.075, HR = 2.49 and p = 0.066, HR = 3.27, respectively. Conclusion: The method for the determination of circulating anti-TF-pAA IgG may be a useful supplement in long-term prognostic assessment of patients with breast cancer. |
uk_UA |
dc.description.sponsorship |
This study was supported by a grant № 8399 from the Estonian Science Foundation. |
uk_UA |
dc.language.iso |
en |
uk_UA |
dc.publisher |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |
uk_UA |
dc.relation.ispartof |
Experimental Oncology |
|
dc.subject |
Original contributions |
uk_UA |
dc.title |
The level of IgG antibodies reactive to TF, Tn and Alpha-Gal polyacrylamide-glycoconjugates in breast cancer patients: relation to survival |
uk_UA |
dc.type |
Article |
uk_UA |
dc.status |
published earlier |
uk_UA |
Файли у цій статті
Ця стаття з'являється у наступних колекціях
Показати простий запис статті